|1.||Grant, Steven: 8 articles (10/2013 - 11/2009)|
|2.||Dent, Paul: 8 articles (10/2013 - 11/2009)|
|3.||Viallet, Jean: 7 articles (10/2010 - 03/2008)|
|4.||Shiau, Chung-Wai: 5 articles (02/2015 - 08/2012)|
|5.||Chen, Kuen-Feng: 5 articles (02/2015 - 08/2012)|
|6.||Su, Jung-Chen: 5 articles (02/2015 - 08/2012)|
|7.||Berger, Mark: 5 articles (12/2014 - 12/2008)|
|8.||Tai, Wei-Tien: 4 articles (07/2014 - 08/2012)|
|9.||Liu, Chun-Yu: 4 articles (07/2014 - 08/2012)|
|10.||Takebe, Naoko: 3 articles (12/2015 - 11/2010)|
10/01/2010 - "In vivo, GX15-070 was given after vaccination so as to not negatively impact the induction of vaccine-mediated immunity, resulting in increased intratumoral activated CD8:Treg ratio and significant reduction of pulmonary tumor nodules. "
09/01/2014 - "Pan-Bcl-2 family inhibitor obatoclax has been demonstrated to be effective against various cancers, of which the mechanism of action is not fully understood. "
11/15/2014 - "This method is robust and has been successfully employed in a Children's Oncology Group Phase 1 Consortium study of obatoclax in children with cancer. "
09/01/2014 - "This study may shed a new light on the anti-cancer activity of obatoclax in relation to cell cycle arrest."
08/15/2011 - "The pan Bcl-2 family antagonist Obatoclax (GX15-070), currently in clinical trials, was shown to sensitize TRAIL-resistant tumors to TRAIL-mediated apoptosis via the release of Bak and Bim from Mcl-1 or Bcl-2/Bcl-XL complexes or by the activation of Bax, though other mechanisms were not examined. "
|2.||Hematologic Neoplasms (Hematological Malignancy)
03/01/2012 - "Obatoclax may not prove to have dramatic single agent activity for hematological neoplasms. "
03/01/2012 - "The pan Bcl-2 family member BH3 domain mimetic obatoclax (GX15-070) is currently under clinical evaluation in solid tumors and hematological neoplasms. "
09/01/2008 - "GX15-070/Obatoclax is a small-molecule BH3 mimetic compound that has shown activity against several hematologic malignancies and solid tumors. "
12/15/2008 - "A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies."
01/01/2013 - "By understanding the molecular underpinnings of obatoclax response, along with optimal therapeutic regimens and indications, the potential of obatoclax mesylate for the treatment of hematological malignancies may be further clarified."
|3.||Glioblastoma (Glioblastoma Multiforme)
11/01/2014 - "We emphasize the functional relation between Bcl-2 proteins and radiosensitization by HDACi and provide a target for increasing responsiveness in glioblastoma by using the Bcl-2 inhibitor Obatoclax. "
06/10/2015 - "In this study, we show that combined treatment with ABT263 and GX15-070 overcomes apoptotic resistance in established glioblastoma cell lines, glioma stem-like cells and primary cultures. "
06/10/2015 - "In conclusion, combined treatment with ABT263 and GX15-070 results in a significantly enhanced anti-cancer activity in vitro as well as in vivo in the setting of glioblastoma. "
11/01/2014 - "We study the efficacy of SAHA/RTx and LBH589/RTx when manipulating Bcl-2 family proteins using the Bcl-2 inhibitor Obatoclax in patient-derived glioblastoma stem-like cell (GSC) cultures. "
11/01/2014 - "The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells."
|4.||Breast Neoplasms (Breast Cancer)
07/01/2014 - "We examined the efficacy and drug mechanism of an obatoclax analog SC-2001, a novel STAT3 inhibitor, in human breast cancer cells. "
07/01/2014 - "Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells."
02/01/2013 - "RT-PCR arrays can predict the relative apoptosis response of breast cancer cells to the pan Bcl-2 inhibitor obatoclax alone or when combined with radiation."
11/01/2010 - "Collectively our data demonstrate that manipulation of MCL-1 protein expression by CDK inhibition or inhibition of sequestering function MCL-1 by Obatoclax renders breast cancer cells more susceptible to BAX/BAK-dependent mitochondrial dysfunction and tumor cell death."
04/01/2013 - "Here, we show that GX15-070 is more effective in reducing the cell density of antiestrogen-resistant breast cancer cells versus sensitive cells and that this increased sensitivity of resistant cells to GX15-070 correlates with an accumulation of autophagic vacuoles. "
|5.||Thyroid Neoplasms (Thyroid Cancer)
01/01/2015 - "With these experiments we demonstrated the efficacy of the BH3 mimetic drug GX15-070 acting against dedifferentiated thyroid carcinoma cells of various histological origins by the induction of cell death. "
01/01/2015 - "The purpose of this study was to analyze the molecular effects of the BH3 mimetic GX15-070 on thyroid carcinoma cell lines and to characterize cell death induced by GX15-070. "
01/01/2015 - "Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cells."
|2.||Proteins (Proteins, Gene)
|4.||Estrogen Receptor Modulators (Antiestrogen)
|10.||Etoposide (VP 16)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)